Wal-zan label

Wal-zan

Wal-zan Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

WARNINGS

Cardiovascular Effects

Cardiovascular Thrombotic Events

Clinical trials of several COX – 2 selective and nonselective NSAIDs of up to three years duration have

shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke,

which can be fatal. All NSAIDs, both COX – 2 selective and nonselective, may have a similar risk.

Patients with a known CV disease or risk factors for CV disease may be at greater risk. To minimize the

potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest

duration possible. Physicians and patients should remain alert for the

development of such events, even in the absence of previous CV symptoms. Patients should be

informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.

There is not consistent evidence that concurrent use of aspirin mitigates the increased risk of serious

CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does

increase the risk of serious GI events (see WARNINGS, GASTROINTESTINAL EFFECTS -RISK OF

ULCERATION, BLEEDING AND PERFORATION).

Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first

10  – 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke (see

CONTRAINDICATIONS).

Hypertension

NSAIDs including ibuprofen tablets, can lead to onset of new hypertension or worsening of

pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Patients

taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs.

NSAIDs, including ibuprofen tablets, should be used with caution in patients with hypertension. Blood

pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course

of therapy.

Congestive Heart Failure and Edema.

Fluid retention and edema have been observed in some patients taking NSAIDs. Ibuprofen tablets

should be used with caution in patients with fluid rentention or heart failure.

Gastrointestinal Effects – Risk of Ulceration, Bleeding and Perforation

NSAIDs, including ibuprofen tablets, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of

the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in

patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers,

gross bleeding, or perforation caused by NSAIDs occur in approximately 1 % of patients treated for 3 – 6 months, and in about 2 – 4 % of patients treated for one

year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of

therapy. However, even short – term therapy is not without risk. NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer

disease or gastrointestinal bleeding. Patients with a prior history of peptic ulcer disease and / or gastrointestinal bleeding who use NSAIDs have a greater

than 10 – fold increased risk for developing a GI bleed compared to patients treated with neither of these risk factors. Other factors that increase the risk of

GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy,

smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated

patients and therefore, special care should be taken in treating this population.

To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest

possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulcerations and bleeding during NSAID therapy and

promptly initiate additional evaluation and treatment is a serious GI event is suspected. This should include discontinuation of the NSAID until a

serious GI adverse event is ruled out. For high – risk patients, alternate therapies that do not involve NSAIDs should be considered.

Renal Effects

Long – term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients

in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a NSAID

may cause a dose – dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decomposition.

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors,

and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

Advanced Renal Disease

No information is available from controlled clinical studies regarding the use of ibuprofen tablets in patients with advanced renal disease. Therefore,

treatment with ibuprofen tablets is not recommended in those patients with advanced renal disease. If ibuprofen tablet therapy must be initiated,

close monitoring of the patients renal function is advisable.

Anaphylactoid Reactions

As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ibuprofen tablets. Ibuprofen tablets should not

be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal

polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS,

Preexisting Asthma). Emergency help should be sought in cases where an anaphylactoid reaction occurs.

Skin Reactions

NSAIDs, including ibuprofen tablets, can cause serious skin adverse events such as exfoliative dermatitis. Stevens – Johnson Syndrome (SJS), and

toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs

and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other

sign of hypersensitivity.

Pregnancy

In late pregnancy, as with other NSAIDs, ibuprofen tablets should be avoided because it may cause premature closure of the ductus arteriosus.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

INDICATIONS AND USAGE

Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options

before deciding to use ibuprofen tablets. Use the lowest effective dose for the shortest duration

consistent with individual patient treatment goals (see WARNINGS).

Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and

osteoarthritis.

Ibuprofen tablets are indicated for the relief of mild to moderate pain.

Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea.

Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have

not been conducted.

History

There is currently no drug history available for this drug.

Other Information

Each tablet contains: Ibuprofen, USP ……800 mg

Ibuprofen tablets contain the active ingredient ibuprofen, which is (+/-) – 2 – (p – isobutylphenyl)

propionic acid. Ibuprofen is a white powder with a melting point of 74 – 77 C and is very slightly soluble

in water  (less than 1 mg / mL) and readily soluble in organic solvents such as ethanol and acetone.

Ibuprofen tablets, a nonsteroidal anti – inflammatory drug (NSAID), are available in 400 mg, 600 mg and

800 mg tablets for oral administration. Inactive ingredients: colloidal silicon dioxide, croscarmellose

sodium, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol,

pregelatinized starch, talc and titanium dioxide.

Wal-zan Manufacturers

  • Walgreens Company
    Wal-zan | Alivio Medical Products, Llc
    No Recall

    Wal-zan | Alivio Medical Products, Llc

    Wal-zan | Alivio Medical Products, Llc

    DOSAGE AND USE: See package insert for complete product information

    DOSAGE AND ADMINISTRATION

    Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen tablets. Use the lowest

    effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

    After observing the response to initial therapy with ibuprofen tablets, the dose and frequency should be adjusted to suit an individual patient's needs.

    Do not exceed 3200 mg total daily dose. If gastrointestinal complaints occur, administer ibuprofen tablets with meals or milk.

    Rheumatoid arthritis and osteoarthritis, including flare - ups of chronic disease

    Suggested Dosage: 1200 mg - 3200 mg daily (300 mg qid; 400 mg, 600 mg or 800 mg tid or qid). Individual patients may show a better response to 3200 mg

    daily, as compared with 2400 mg, although in well - controlled clinical trials patients on 3200 mg did not show a better mean response in terms of efficacy.

    Therefore, when treating patients with 3200 mg / day, the physician should observe sufficient increased clinical benefits to offset potential increased risk.

    The dose should be tailored to each patient, and may be lowered or raised depending on the severity of symptoms either at the time of initiating drug therapy or

    as the patient responds or fails to respond.

    In general, patients with rheumatoid arthritis seem to require higher doses of ibuprofen tablets than do patients with osteoarthritis.

    The smallest dose of ibuprofen tablets that yields acceptable control should be employed. A linear blood level dose - response relationship exists with single

    doses up to 800 mg (See CLINICAL PHARMACOLOGY for effects of food on rate of absorption).

    The availability of four tablet strengths facilitates dosage adjustment.

    In chronic conditions, a therapeutic response to therapy with ibuprofen tablets is sometimes seen in a few days to a week but most often is observed by two

    weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required.

    Mild to moderate pain: 400 mg every 4 to 6 hours as necessary for relief of pain.

    In controlled analgesic clinical trials, doses of ibuprofen tablets greater than 400 mg were no effective than the 400 mg dose.

    Dysmenorrhea

    For the treatment of dysmenorrhea, beginning with the earliest onset of such pain, ibuprofen tablets should be given in a dose of 400 mg every 4 hours as

    necessary for the relief of pain.

  • Walgreen Company
    Wal-zan | Cantrell Drug Company
    No Recall

    Wal-zan | Cantrell Drug Company

    Wal-zan | Cantrell Drug Company

    There is currently no dosage information available for this product. We apologize for any inconvenience.

  • Walgreens Company
    Wal-zan | Walgreens Company
    No Recall

    Wal-zan | Walgreens Company

    Wal-zan | Walgreens Company

    adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor